PXD069599-1

PXD069599 is an original dataset announced via ProteomeXchange.

Title	BOLD-100 treatment induces systemic lipid crosstalk in metastatic colorectal carcinoma patients in a combination treatment with FOLFOX
Description	BOLD-100 (sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)]) is a clinical stage anticancer drug candidate that targets GRP78 and impacts the ER stress responses in cancer cells. Despite expanding knowledge about its multimodal mechanism of action from preclinical studies, little is known about the metabolic effects of BOLD-100 effects in patients. This study is an exploratory analysis of the blood plasma from a subset of metastatic colorectal carcinoma (mCRC) patients who were participants in a Phase 1b/2a dose escalation study (NCT04421820) using a multi-omic strategy, based on proteomic and fatty acid/oxylipin analysis. BOLD-100 treatment was found to exhibit systemic, dose-dependent effects that were more pronounced on the fatty acid/oxylipin level compared to the protein level. The dose-dependent effects were characterized by increased abundances of multiple pro-inflammatory and -resolving mediators. Those were paralleled by increased APOC1 and decreased CD5L abundances, which may represent a physiological response to the liberated fatty acids and oxylipins. Altered abundances of CDF and APOC2-3 indicate further lipid crosstalk between adipocytes and lipoproteins from the liver, respectively. Finally, a potential prognostic marker signature featuring increased abundance of LGALS3BP and decreased abundance of arachidonic acid and 5-HETE correlated with progression-free survival in these patients. This study indicates that BOLD-100 affects fatty acid/oxylipin profiles and influences systemic lipid crosstalk, which, in combination with FOLFOX chemotherapy, may at least partially account for the superior clinical outcomes over established therapies in mCRC patients.
HostingRepository	PRIDE
AnnounceDate	2026-07-27
AnnouncementXML	Submission_2026-07-27_03:23:22.479.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Christopher Gerner
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	iodoacetamide derivatized residue
Instrument	timsTOF Pro

Revision	Datetime	Status	ChangeLog Entry
0	2025-10-17 12:13:30	ID requested
⏵ 1	2026-07-27 03:23:22	announced

Dataset with its publication pending

submitter keyword: BOLD-100

Cancer

Drug Development

Fatty acids

FOLFOX

KP1339

Multi-omics

Metals in Medicine

Oxylipins

Plasma

Proteomics

Christopher Gerner
contact affiliation	University of Vienna, Faculty of Chemistry, Department of Analytical Chemistry
contact email	christopher.gerner@univie.ac.at
lab head
Christopher Gerner
contact affiliation	University of Vienna
contact email	christopher.gerner@univie.ac.at
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/07/PXD069599

PRIDE project URI

• PRIDE
  1. PXD069599
     1. Label: PRIDE project
     2. Name: BOLD-100 treatment induces systemic lipid crosstalk in metastatic colorectal carcinoma patients in a combination treatment with FOLFOX